Market Place
Sourcing Support
FDA blasts Bristol Myers over misleading Krazati efficacy claims
08 Aug 2024 //
FIERCE PHARMA
BMS cuts hundreds of Mirati staffers shortly after buyout
27 Mar 2024 //
FIERCE PHARMA
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics
23 Jan 2024 //
BUSINESSWIRE
Bristol Myers gets regulatory clearance to close Mirati deal
20 Dec 2023 //
ENDPTS
EU body endorses Mirati`s KRAS drug for lung cancer after second look
11 Nov 2023 //
PR NEWSWIRE
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration
02 Nov 2023 //
GLOBENEWSWIRE
Securities filing details BMS` years-long courtship of Mirati
24 Oct 2023 //
FIERCE PHARMA
Mirati Presents Results Evaluating the Combination of Adagrasib in NSCLC
17 Oct 2023 //
PRESS RELEASE
Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal
09 Oct 2023 //
REUTERS
Sanofi weighs acquisition of Mirati: Bloomberg
05 Oct 2023 //
FIERCE PHARMA
Mirati To Present Updated Clinical Data at ESMO Congress 2023
27 Sep 2023 //
PRESS RELEASE
Mirati Presents Data from KRYSTAL-1 Study Demonstrating Durable Response
09 Sep 2023 //
PR NEWSWIRE
Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
05 Sep 2023 //
PRESS RELEASE
Bazhenova Details Potential Pathways Forward for Targeting KRAS in NSCLC
28 Aug 2023 //
ONCLIVE
Mirati Announces Departure of Chief Financial Officer Laurie Stelzer
23 Aug 2023 //
PR NEWSWIRE
Mirati Announces Closing of Upsized Public Offering
11 Aug 2023 //
PRESS RELEASE
Mirati Therapeutics Announces Pricing of Upsized Public Offering
09 Aug 2023 //
PRESS RELEASE
Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719
09 Aug 2023 //
PR NEWSWIRE
Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek
08 Aug 2023 //
PRESS RELEASE
Mirati Therapeutics Announces Proposed Public Offering
08 Aug 2023 //
PRESS RELEASE
Mirati Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
PR NEWSWIRE
Mirati parts ways with CEO, unveils new KRAS-Keytruda trial plan
08 Aug 2023 //
FIERCE PHARMA
Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
03 Aug 2023 //
PRESS RELEASE
DOJ accuses billionaire of insider trading in Solid Bio, Mirati
26 Jul 2023 //
FIERCE BIOTECH
Mirati Therapeutics® to Report Second Quarter 2023 Financial Results
25 Jul 2023 //
PRESS RELEASE
Mirati`s lung cancer drug fails to win EU regulator`s backing
22 Jul 2023 //
PRESS RELEASE
Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D as New Independent Director
23 Jun 2023 //
PR NEWSWIRE
Journal of Clinical Oncology Publishes Clinical Results of Adagrasib
20 Jun 2023 //
PRESS RELEASE
Mirati to Participate at the Goldman Sachs 44th Annual Global Conference 2023
02 Jun 2023 //
FINANCE YAHOO
Mirati`s wait for next lung cancer med ends in phase 3 failure
25 May 2023 //
FIERCE BIOTECH
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study
24 May 2023 //
PRESS RELEASE
Mirati`s KRAS drug Krazati beat estimates in first full quarter
11 May 2023 //
FIERCE PHARMA
Mirati Therapeutics Reports First Quarter 2023 Financial Results
09 May 2023 //
PRESS RELEASE
Mirati Therapeutics & Sarah Cannon Research Institute Announce Strategi
08 May 2023 //
BIOSPACE
Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
05 May 2023 //
PRESS RELEASE
Next round of KRAS drugs follow footsteps of Amgen and Mirati
04 May 2023 //
FIERCE BIOTECH
Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference
06 Mar 2023 //
PR NEWSWIRE
Mirati to Participate at the 43rd Annual Cowen Health Care Conference
21 Feb 2023 //
PRESS RELEASE
Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results
14 Feb 2023 //
PRESS RELEASE
Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
03 Feb 2023 //
PRESS RELEASE
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
01 Feb 2023 //
PR NEWSWIRE
Mirati Announces IND Clearance by FDA Enabling Phase 1 Initiation for MRTX1133
19 Jan 2023 //
PR NEWSWIRE
Mirati eyes `highest opportunity for capital` in pipeline build
10 Jan 2023 //
FIERCEBIOTECH
Apple Tree biotech emerges with antibodies that might pair with KRAS drugs
09 Jan 2023 //
ENDPTS
JPM23, Day 1: Lilly`s busy schedule, Mirati`s new pipeline
09 Jan 2023 //
FIERCE BIOTECH
Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
06 Jan 2023 //
PRESS RELEASE
Don`t Ignore The Insider Selling In Mirati Therapeutics
28 Dec 2022 //
SIMPLYWALL
Mirati to Present at the 41st Annual J.P. Morgan Healthcare Conference
22 Dec 2022 //
PRESS RELEASE
Mirati announces AdagrasibReceives Breakthrough Therapy Designation from FDA
21 Dec 2022 //
PRESS RELEASE
Mirati Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
13 Dec 2022 //
PRESS RELEASE
QIAGEN receives FDA approval for companion diagnostic to Mirati’s KRAZATI
13 Dec 2022 //
BUSINESSWIRE
U.S. FDA approves Mirati`s lung cancer drug Adagrasib
13 Dec 2022 //
PRNEWSWIRE
Mirati to focus KRAS inhibitor, Keytruda combo on low PD-L1 lung cancer
07 Dec 2022 //
FIERCEBIOTECH
Mirati Therapeutics Presents Results Evaluating Adagrasib and Pembrolizumab
05 Dec 2022 //
PRESS RELEASE
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study
02 Dec 2022 //
PRESS RELEASE
Mirati`s sitravatinib yet to improve survival at interim review
02 Dec 2022 //
FIERCEBIOTECH
Mirati Therapeutics to Present Late-Breaking Combination Results at ESMO IO
28 Nov 2022 //
PRESS RELEASE
Mirati gauging sale interest of Big Pharmas — report
23 Nov 2022 //
ENDPTS
Mirati is once again the subject of takeover talks: report
23 Nov 2022 //
FIERCEBIOTECH
